Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Green Thumb Industries (OtherGTBIF)

Tipranks - Tipranks - Sat Apr 4, 12:02PM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vertex Pharmaceuticals (VRTX) and Green Thumb Industries (GTBIF).

End of Quarter Sale - 50% Off TipRanks

Vertex Pharmaceuticals (VRTX)

In a report released yesterday, Hans Engel from Erste Group maintained a Hold rating on Vertex Pharmaceuticals. The company’s shares closed last Thursday at $438.71.

According to TipRanks.com, Engel is a 4-star analyst with an average return of 8.5% and a 53.7% success rate. Engel covers the Healthcare sector, focusing on stocks such as Boston Scientific, Johnson & Johnson, and Merck & Company. ;'>

Currently, the analyst consensus on Vertex Pharmaceuticals is a Strong Buy with an average price target of $556.74, which is a 24.4% upside from current levels. In a report issued on March 29, TipRanks – Anthropic also downgraded the stock to Hold with a $472.00 price target.

See today’s best-performing stocks on TipRanks >>

Green Thumb Industries (GTBIF)

Canaccord Genuity analyst Kenric Tyghe maintained a Buy rating on Green Thumb Industries yesterday and set a price target of C$18.00. The company’s shares closed last Thursday at $6.72, close to its 52-week low of $5.37.

According to TipRanks.com, Tyghe is a 4-star analyst with an average return of 16.2% and a 51.8% success rate. Tyghe covers the Healthcare sector, focusing on stocks such as Planet 13 Holdings, Organigram Global, and Aurora Cannabis. ;'>

Currently, the analyst consensus on Green Thumb Industries is a Strong Buy with an average price target of $15.08, which is a 141.7% upside from current levels. In a report issued on March 29, TipRanks – PerPlexity also reiterated a Buy rating on the stock with a C$9.00 price target.

Read More on VRTX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).